Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2010

01-12-2010 | Gastrointestinal Oncology

The Fibroblast Growth Factor Receptor-4 Arg388 Allele is Associated with Gastric Cancer Progression

Authors: Yanwei Ye, MD, Yingqiang Shi, MD, Ye Zhou, MD, Chunyan Du, MD, Chunmeng Wang, MD, Heqin Zhan, PhD, Biqiang Zheng, PhD, Xi Cao, MD, Meng-hong Sun, MD, Hong Fu, MD

Published in: Annals of Surgical Oncology | Issue 12/2010

Login to get access

Abstract

Background

Fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism, located in the FGFR4 gene exon 9, was reported to be associated with malignant tumors prognosis; however, there has been no relevant research for gastric cancer. The purpose of this study was to investigate the clinical significance of FGFR4 Gly388Arg polymorphism as well as the mRNA expression of FGFR4 in patients with gastric cancer.

Methods

The mRNA expression of FGFR4 in 103 gastric cancer tissues and corresponding normal tissues were measured by reverse transcription polymerase chain reaction (PCR) and real-time quantitative PCR. PCR-restriction fragment length polymorphism analysis was performed to detect the FGFR4 Gly388Arg in 103 gastric cancer tissues.

Results

In 57.3% of patients, homozygous or heterozygous Arg388 allele was present. FGFR4 expressions in mRNA levels were higher in gastric cancer tissues compared with those in relevant normal tissues. However, there is no significantly statistical difference compared with mRNA expression of FGFR4 in different genotypes. Associations between FGFR4 Gly388Arg polymorphism and overall survival exist in patients with gastric cancer (P = 0.046).The FGFR4 Arg allele (hazard risk (HR), 2.324; 95% confidence interval (CI), 1.054–4.125; P = 0.037) and TNM stage (HR, 5.516; 95% CI 3.658–7.409; P = 0.005) were independent prognostic factors in patients with gastric cancer.

Conclusions

Based on this study, FGFR4 Arg388 genotype—a marker for gastric cancer progression—may predict prognosis of gastric cancer.
Literature
1.
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMed
2.
Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res. 1992;59:115–65.CrossRefPubMed
3.
Ozen M, Giri D, Ropiquet F, et al. Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. J Natl Cancer Inst (Bethesda). 2001;93:1783–90.
4.
Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–49.CrossRefPubMed
5.
Wang J, Stockton DW, Ittmann M. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res. 2004;10:6169–78.CrossRefPubMed
6.
Bange J, Prechtl D, Cheburkin Y, et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res. 2002;62:840–7.PubMed
7.
Nakamura N, Iijima T, Mase K, et al. Phenotypic differences of proliferating fibroblasts in the stroma of lung adenocarcinoma and normal bronchus tissue. Cancer Sci. 2004;95:226–32.CrossRefPubMed
8.
Kan M, Wu X, Wang F, et al. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem. 1999;274:15947–52.CrossRefPubMed
9.
Lin BC, Wang M, Blackmore C, et al. Liver-specific activities of FGF19 require Klotho beta. J Biol Chem. 2007;282:27277–84.CrossRefPubMed
10.
Leung HY, Gullick WJ, Lemoine NR. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994;59:667–75.CrossRefPubMed
11.
Takahashi A, Sasaki H, Kim SJ, et al. Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique. Biochem Biophys Res Commun. 1999;257:855–9.CrossRefPubMed
12.
Thussbas C, Nahrig J, Streit S, et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol. 2006;24:3747–55.CrossRefPubMed
13.
Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005;23:7307–11.CrossRefPubMed
14.
Streit S, Bange J, Fichtner A, et al. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer. 2004;111:213–7.CrossRefPubMed
15.
Morimoto Y, Ozaki T, Ouchida M, et al. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma. Cancer. 2003;98:2245–50.CrossRefPubMed
16.
Ma Z, Tsuchiya N, Yuasa T, et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer. 2008;123:2574–9.CrossRefPubMed
17.
Falvella FS, Frullanti E, Galvan A, et al. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. Int J Cancer. 2009;124:2880–5.CrossRefPubMed
18.
Tanuma J, Izumo T, Hirano M, et al. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma. Oncol Rep. 2010;23:739–44.PubMed
19.
Matakidou A, El Galta R, Rudd MF, et al. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis. Br J Cancer. 2007;96:1904–7.CrossRefPubMed
20.
Yang YC, Lu ML, Rao JY, et al. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis. Br J Cancer. 2006;95:1455–8.CrossRefPubMed
21.
Ho CK, Anwar S, Nanda J, et al. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis. 2010;13:94–6.CrossRefPubMed
22.
Naidu R, Har YC, Taib NA. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development. Oncol Res. 2009;18:65–71.CrossRefPubMed
23.
Ho HK, Pok S, Streit S, et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol. 2009;50:118–27.CrossRefPubMed
Metadata
Title
The Fibroblast Growth Factor Receptor-4 Arg388 Allele is Associated with Gastric Cancer Progression
Authors
Yanwei Ye, MD
Yingqiang Shi, MD
Ye Zhou, MD
Chunyan Du, MD
Chunmeng Wang, MD
Heqin Zhan, PhD
Biqiang Zheng, PhD
Xi Cao, MD
Meng-hong Sun, MD
Hong Fu, MD
Publication date
01-12-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1323-6

Other articles of this Issue 12/2010

Annals of Surgical Oncology 12/2010 Go to the issue

Pediatric Oncology

Outcomes of Pediatric Patients with Malignancies of the Major Salivary Glands

Melanomas

The Prognostic Significance of Nonsentinel Lymph Node Metastasis in Melanoma

Bone and Soft Tissue Sarcomas

Prognostic Implication of Ezrin Overexpression in Myxofibrosarcomas

Translational Research and Biomarkers

Jun Activation Domain Binding Protein 1 is Overexpressed from the Very Early Stages of Hepatocarcinogenesis

Gastrointestinal Oncology

Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients

Hepatobiliary Tumors

Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial